Drug intelligence / Profile preview

atazanavir + ritonavir + tenofovir disoproxil fumarate + emtricitabine

Development stage
Unknown
Lead developer
Bristol Myers Squibb
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination antiretroviral therapy regimen used for the treatment of HIV-1 infection. It combines four medications: atazanavir (a protease inhibitor), ritonavir (a pharmacokinetic enhancer/booster), and the nucleoside/nucleotide reverse transcriptase inhibitors tenofovir disoproxil fumarate and emtricitabine. Atazanavir is boosted with low-dose ritonavir to optimize its pharmacokinetic parameters and efficacy. This combination has shown potent antiviral activity with once-daily dosing, making it suitable for initial HIV treatment or as part of a treatment regimen for HIV-infected individuals.

Brand names
Truvada
Other names
ATV/r + FTC/TDFatazanavir/ritonavir + emtricitabine/tenofovir disoproxil fumarate
02

Targets

Human immunodeficiency virus type 1 reverse transcriptaseCYP3A4 (Cytochrome P450 3A4)PR (Progesterone receptor)

Beyond the preview

Go deeper on atazanavir + ritonavir + tenofovir disoproxil fumarate + emtricitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on atazanavir + ritonavir + tenofovir disoproxil fumarate + emtricitabine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call